Is long-term adjuvant treatment of breast cancer with anastrozole indicated?

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 9, 2008, Pages 1619-1622

  Doggrell, Sheila A ^a  

^a RMIT UNIVERSITY   (Australia)

Author keywords

Anastrozole; Breast cancer; Clinical trials; Tamoxifen

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; EXEMESTANE; FASOLEX; FULVESTRANT; LETROZOLE; PLACEBO; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; NITRILE; TRIAZOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BONE PAIN; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG POTENTIATION; DRUG RECEPTOR BINDING; ENDOMETRIUM CANCER; FRACTURE; HAIR LOSS; HOT FLUSH; HUMAN; LONG TERM CARE; MONOTHERAPY; MUSCULOSKELETAL DISEASE; NAUSEA; PATIENT COMPLIANCE; POSTMENOPAUSE; SKIN TOXICITY; SOMNOLENCE; TREATMENT DURATION; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINAL DRYNESS; VENOUS THROMBOEMBOLISM; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; DISEASE FREE SURVIVAL; FEMALE; METHODOLOGY; TIME;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; NITRILES; TIME FACTORS; TRIAZOLES;

EID: 46749088677     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.9.1619     Document Type: Article

References (9)

1. Early Breast Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717
2. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-9
3. Howell A, Cuzick J, Baum M, et al. ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) Trial after completion of 5 years' adjuvant treatment of breast cancer. Lancet 2005;365:60-2
4. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45-53
5. Schmid M, Jakesz R, Samonigg H, et al. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6. J Clin Oncol 2003;21:984-90
6. Jakesz R, Greil R, Gnant M, et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst 2007;99:1845-53
7. Goss PE, Ingle JN, Martino Set al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: update findings from NIC CTG MA.17. J Natl Cancer Inst 2005;97:1262-71
8. Howell A. Pure oestrogen antagonists for the treatment of advanced breast cancer. Endocr Relat Cancer 2006;13:689-707
9. Clinical trials: SOFEA. Available from: http://www.icr.ac.uk/research/ research_sections/clinical_trials/clinical_trials_list/ 1596_modality.shtml